摘要
目的探讨蜂毒肽对胶原诱导关节炎大鼠模型免疫调节的影响。方法成功建立胶原诱导关节炎大鼠模型,随机分为模型组、蜂毒肽(0.5 mg/kg)组、甲氨蝶呤(1 mg/只)组,每组6只,另选取未造模大鼠为对照组;造模第14天起,隔日1次ip蜂毒肽,每周1次ip甲氨蝶呤,对照组、模型组ip等量生理盐水,给药21 d。观察关节肿胀程度、进行关节炎指数(AI)评分;给药结束后,收集血清,ELISA法检测血清中免疫球蛋白G(IgG)、IgG1、IgG2a、干扰素-γ(IFN-γ)、白细胞介素-4(IL-4)水平;分离大鼠脾脏,提取淋巴细胞,流式细胞术检测Th1、Th2细胞比例。结果蜂毒肽组大鼠关节皮肤发红,关节肿胀明显减轻;与模型组比较,蜂毒肽显著抑制AI评分(P<0.05);显著降低血清中IgG、IgG2a、IFN-γ浓度(P<0.05),升高IgG1、IL-4浓度(P<0.05);显著下调Th1细胞比例、Th1/Th2比值(P<0.05),上调Th2细胞比例(P<0.05)。结论蜂毒肽能通过调节Th1/Th2平衡抑制胶原诱导关节炎大鼠的炎症。
Objective To investigate the effect of melittin on the immune regulation of arthritis rat model induced by collagen.Methods The arthritis rat model was successfully established and randomly divided into model group,melittin group and methotrexate group with six rats in each group.In addition,rats without modeling were selected as control group.After 14 d,the melittin were ip injected once every other day and methotrexate were ip given once a week for 21 d.The model group was given the same amount of normal saline,and the degree of joint swelling was observed and calculated.After drug administration,the serum was collected from rats,and the serum levels of IgG,IgG1,IgG2a,IFN-γ,and IL-4 were detected by ELISA.The spleen was isolated from rats and lymphocytes were extracted.The proportion of Th1 and Th2 cells was detected by flow cytometry.Results In the melittin group,there was redness in the joint skin,and the swelling of the joint was obviously alleviated.Compared with model group,melittin significantly inhibited joint swelling score(P<0.05),reduced the concentrations of IgG,IgG2a,and IFN-γin serum(P<0.05),increased concentrations of IgG1 and IL-4(P<0.05),down-regulated the ratio of Th1 cells and the ratio of Th1/Th2(P<0.05),and up-regulated the ratio of Th2 cells(P<0.05).Conclusion Melittin can inhibit the inflammation in the collageninduced arthritis by regulating Th1/Th2 balance.
作者
贺守第
范钊坤
关丽
黎德育
杨平常
刘志刚
黄胜光
HE Shoudi;FAN Zhaokun;GUAN Li;LI Deyu;YANG Pingchang;LIU Zhigang;HUANG Shengguang(Traditional Chinese Medicine Department of Rheumatism,Shenzhen Nanshan People's Hospital,Shenzhen 518060,China;Institute of Allergy and Immunology,Shenzhen University,Shenzhen 518060,China;Department of Rheumatological Immunology,Luohu District people's Hospital,Shenzhen 518060,China;Department of intensiveMedicine,the first affiliatedHospital of ZhejiangUniversity of traditionalChineseMedicine,Hangzhou,310000,China)
出处
《药物评价研究》
CAS
2019年第3期444-449,共6页
Drug Evaluation Research
基金
国家自然科学基金(81271950)
深圳市科技计划基础研究项目(JCYJ20170307162827158
JCYJ20160429183052202)
深圳市卫生计生科研项目(201506091
201606050)
深圳市南山区科技项目(2015021
2015043
2015047
2017016)
